CCB, a novel specific κ opioid agonist, which discriminates between opioid and σ 1 recognition sites
CCB, 6,11 -Dimethyl-1,2,3,4,5,6-hexahydro-3-{[2′-methoxycarbonyl-2′-(4-chlorophenyl) cyclopropyl]methyl}-2,6-methano-3-benzazocin-8-ol, displays specificity and very high affinity for κ opioid receptor types (K 1 = 0.41 ± 0.19 nM). In contrast to other κ opioid agonists, CCB is also selective with r...
Gespeichert in:
| Veröffentlicht in: | Life sciences (1973) 1995, Vol.57 (16), p.1487-1495 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1495 |
|---|---|
| container_issue | 16 |
| container_start_page | 1487 |
| container_title | Life sciences (1973) |
| container_volume | 57 |
| creator | Ronsisvalle, G. Prezzavento, O. Pasquinucci, L. Marrazzo, A. Vittorio, F. Gomez-Vidal, J.A. Carboni, L. Spampinato, S. |
| description | CCB, 6,11 -Dimethyl-1,2,3,4,5,6-hexahydro-3-{[2′-methoxycarbonyl-2′-(4-chlorophenyl) cyclopropyl]methyl}-2,6-methano-3-benzazocin-8-ol, displays specificity and very high affinity for κ opioid receptor types (K
1 = 0.41 ± 0.19 nM). In contrast to other κ opioid agonists, CCB is also selective with respect to σ
1 sites (K
1 = 1,050 ± 55 nM). CCB displays antinociceptive and sedative effects in the mouse comparable to those of U50,488H and morphine. Naltrexone fully antagonizes these effects. The sedative effects of CCB are blocked in mice pretreated with naltrexone or nor-BNI. CCB and U50,488H produce a superimposable diuresis in rats. Naltrexone and nor-BNI, both are effective in antagonizing the effect. CCB does not produce any stereotyped behavior or ataxia in the behavioral assay in doses up to 40 mg/kg s.c., These findings suggest that CCB might be a useful tool to investigate the physiological role of κ opioid receptors. |
| doi_str_mv | 10.1016/0024-3205(95)02120-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_77517639</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0024320595021208</els_id><sourcerecordid>77517639</sourcerecordid><originalsourceid>FETCH-LOGICAL-e1083-37260fba14a666b51392681bb495cdd005bd415b93859ca535b9efe4417fa3b93</originalsourceid><addsrcrecordid>eNo9kc9KAzEQxoMotVbfQCEnUehqstlkdy-CLv6Dghc9h2wy20bapG62LZ59Kx9CX8nUlp5mmPkxfN83CJ1SckUJFdeEpFnCUsIvSn5JUpqSpNhDfVrkZUIEo_uov0MO0VEI74QQznPWQ72ci6woWR81VXU3xAo7v4QpDnPQtrEa_3xjP7feGqzG3tnQDfFqYvUEGxt0a2fWqQ4CrqFbAbgd6wz-_cIUt6D92NnOeoeDjeQxOmjUNMDJtg7Q28P9a_WUjF4en6vbUQKUFCxheSpIUyuaKSFEzSkrU1HQus5Kro2J8muTUV6XrOClVpzFFhrIMpo3isXxAJ1v7s5b_7GA0MlZFAzTqXLgF0HmOae5YGvwbAsu6hkYOY-mVPspt8HE_c1mD1Ht0kIrg7bgNBgbzXXSeCspketHyHXKcp2yLLn8f4Qs2B9gZnnY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77517639</pqid></control><display><type>article</type><title>CCB, a novel specific κ opioid agonist, which discriminates between opioid and σ 1 recognition sites</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Ronsisvalle, G. ; Prezzavento, O. ; Pasquinucci, L. ; Marrazzo, A. ; Vittorio, F. ; Gomez-Vidal, J.A. ; Carboni, L. ; Spampinato, S.</creator><creatorcontrib>Ronsisvalle, G. ; Prezzavento, O. ; Pasquinucci, L. ; Marrazzo, A. ; Vittorio, F. ; Gomez-Vidal, J.A. ; Carboni, L. ; Spampinato, S.</creatorcontrib><description>CCB, 6,11 -Dimethyl-1,2,3,4,5,6-hexahydro-3-{[2′-methoxycarbonyl-2′-(4-chlorophenyl) cyclopropyl]methyl}-2,6-methano-3-benzazocin-8-ol, displays specificity and very high affinity for κ opioid receptor types (K
1 = 0.41 ± 0.19 nM). In contrast to other κ opioid agonists, CCB is also selective with respect to σ
1 sites (K
1 = 1,050 ± 55 nM). CCB displays antinociceptive and sedative effects in the mouse comparable to those of U50,488H and morphine. Naltrexone fully antagonizes these effects. The sedative effects of CCB are blocked in mice pretreated with naltrexone or nor-BNI. CCB and U50,488H produce a superimposable diuresis in rats. Naltrexone and nor-BNI, both are effective in antagonizing the effect. CCB does not produce any stereotyped behavior or ataxia in the behavioral assay in doses up to 40 mg/kg s.c., These findings suggest that CCB might be a useful tool to investigate the physiological role of κ opioid receptors.</description><identifier>ISSN: 0024-3205</identifier><identifier>EISSN: 1879-0631</identifier><identifier>DOI: 10.1016/0024-3205(95)02120-8</identifier><identifier>PMID: 7564893</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer ; Analgesics - pharmacology ; Animals ; Benzomorphans - pharmacology ; Binding, Competitive ; CCB ; Male ; Mice ; Morphine - pharmacology ; Naltrexone - pharmacology ; Pyrrolidines - pharmacology ; Rats ; Rats, Sprague-Dawley ; Receptors, Opioid, delta - drug effects ; Receptors, Opioid, kappa - agonists ; Receptors, Opioid, kappa - drug effects ; specific κ opioid agonist ; δ binding ; κ binding ; μ binding ; σ 1 binding</subject><ispartof>Life sciences (1973), 1995, Vol.57 (16), p.1487-1495</ispartof><rights>1995</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0024-3205(95)02120-8$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7564893$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ronsisvalle, G.</creatorcontrib><creatorcontrib>Prezzavento, O.</creatorcontrib><creatorcontrib>Pasquinucci, L.</creatorcontrib><creatorcontrib>Marrazzo, A.</creatorcontrib><creatorcontrib>Vittorio, F.</creatorcontrib><creatorcontrib>Gomez-Vidal, J.A.</creatorcontrib><creatorcontrib>Carboni, L.</creatorcontrib><creatorcontrib>Spampinato, S.</creatorcontrib><title>CCB, a novel specific κ opioid agonist, which discriminates between opioid and σ 1 recognition sites</title><title>Life sciences (1973)</title><addtitle>Life Sci</addtitle><description>CCB, 6,11 -Dimethyl-1,2,3,4,5,6-hexahydro-3-{[2′-methoxycarbonyl-2′-(4-chlorophenyl) cyclopropyl]methyl}-2,6-methano-3-benzazocin-8-ol, displays specificity and very high affinity for κ opioid receptor types (K
1 = 0.41 ± 0.19 nM). In contrast to other κ opioid agonists, CCB is also selective with respect to σ
1 sites (K
1 = 1,050 ± 55 nM). CCB displays antinociceptive and sedative effects in the mouse comparable to those of U50,488H and morphine. Naltrexone fully antagonizes these effects. The sedative effects of CCB are blocked in mice pretreated with naltrexone or nor-BNI. CCB and U50,488H produce a superimposable diuresis in rats. Naltrexone and nor-BNI, both are effective in antagonizing the effect. CCB does not produce any stereotyped behavior or ataxia in the behavioral assay in doses up to 40 mg/kg s.c., These findings suggest that CCB might be a useful tool to investigate the physiological role of κ opioid receptors.</description><subject>3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer</subject><subject>Analgesics - pharmacology</subject><subject>Animals</subject><subject>Benzomorphans - pharmacology</subject><subject>Binding, Competitive</subject><subject>CCB</subject><subject>Male</subject><subject>Mice</subject><subject>Morphine - pharmacology</subject><subject>Naltrexone - pharmacology</subject><subject>Pyrrolidines - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Opioid, delta - drug effects</subject><subject>Receptors, Opioid, kappa - agonists</subject><subject>Receptors, Opioid, kappa - drug effects</subject><subject>specific κ opioid agonist</subject><subject>δ binding</subject><subject>κ binding</subject><subject>μ binding</subject><subject>σ 1 binding</subject><issn>0024-3205</issn><issn>1879-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kc9KAzEQxoMotVbfQCEnUehqstlkdy-CLv6Dghc9h2wy20bapG62LZ59Kx9CX8nUlp5mmPkxfN83CJ1SckUJFdeEpFnCUsIvSn5JUpqSpNhDfVrkZUIEo_uov0MO0VEI74QQznPWQ72ci6woWR81VXU3xAo7v4QpDnPQtrEa_3xjP7feGqzG3tnQDfFqYvUEGxt0a2fWqQ4CrqFbAbgd6wz-_cIUt6D92NnOeoeDjeQxOmjUNMDJtg7Q28P9a_WUjF4en6vbUQKUFCxheSpIUyuaKSFEzSkrU1HQus5Kro2J8muTUV6XrOClVpzFFhrIMpo3isXxAJ1v7s5b_7GA0MlZFAzTqXLgF0HmOae5YGvwbAsu6hkYOY-mVPspt8HE_c1mD1Ht0kIrg7bgNBgbzXXSeCspketHyHXKcp2yLLn8f4Qs2B9gZnnY</recordid><startdate>1995</startdate><enddate>1995</enddate><creator>Ronsisvalle, G.</creator><creator>Prezzavento, O.</creator><creator>Pasquinucci, L.</creator><creator>Marrazzo, A.</creator><creator>Vittorio, F.</creator><creator>Gomez-Vidal, J.A.</creator><creator>Carboni, L.</creator><creator>Spampinato, S.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>1995</creationdate><title>CCB, a novel specific κ opioid agonist, which discriminates between opioid and σ 1 recognition sites</title><author>Ronsisvalle, G. ; Prezzavento, O. ; Pasquinucci, L. ; Marrazzo, A. ; Vittorio, F. ; Gomez-Vidal, J.A. ; Carboni, L. ; Spampinato, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e1083-37260fba14a666b51392681bb495cdd005bd415b93859ca535b9efe4417fa3b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer</topic><topic>Analgesics - pharmacology</topic><topic>Animals</topic><topic>Benzomorphans - pharmacology</topic><topic>Binding, Competitive</topic><topic>CCB</topic><topic>Male</topic><topic>Mice</topic><topic>Morphine - pharmacology</topic><topic>Naltrexone - pharmacology</topic><topic>Pyrrolidines - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Opioid, delta - drug effects</topic><topic>Receptors, Opioid, kappa - agonists</topic><topic>Receptors, Opioid, kappa - drug effects</topic><topic>specific κ opioid agonist</topic><topic>δ binding</topic><topic>κ binding</topic><topic>μ binding</topic><topic>σ 1 binding</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ronsisvalle, G.</creatorcontrib><creatorcontrib>Prezzavento, O.</creatorcontrib><creatorcontrib>Pasquinucci, L.</creatorcontrib><creatorcontrib>Marrazzo, A.</creatorcontrib><creatorcontrib>Vittorio, F.</creatorcontrib><creatorcontrib>Gomez-Vidal, J.A.</creatorcontrib><creatorcontrib>Carboni, L.</creatorcontrib><creatorcontrib>Spampinato, S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Life sciences (1973)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ronsisvalle, G.</au><au>Prezzavento, O.</au><au>Pasquinucci, L.</au><au>Marrazzo, A.</au><au>Vittorio, F.</au><au>Gomez-Vidal, J.A.</au><au>Carboni, L.</au><au>Spampinato, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CCB, a novel specific κ opioid agonist, which discriminates between opioid and σ 1 recognition sites</atitle><jtitle>Life sciences (1973)</jtitle><addtitle>Life Sci</addtitle><date>1995</date><risdate>1995</risdate><volume>57</volume><issue>16</issue><spage>1487</spage><epage>1495</epage><pages>1487-1495</pages><issn>0024-3205</issn><eissn>1879-0631</eissn><abstract>CCB, 6,11 -Dimethyl-1,2,3,4,5,6-hexahydro-3-{[2′-methoxycarbonyl-2′-(4-chlorophenyl) cyclopropyl]methyl}-2,6-methano-3-benzazocin-8-ol, displays specificity and very high affinity for κ opioid receptor types (K
1 = 0.41 ± 0.19 nM). In contrast to other κ opioid agonists, CCB is also selective with respect to σ
1 sites (K
1 = 1,050 ± 55 nM). CCB displays antinociceptive and sedative effects in the mouse comparable to those of U50,488H and morphine. Naltrexone fully antagonizes these effects. The sedative effects of CCB are blocked in mice pretreated with naltrexone or nor-BNI. CCB and U50,488H produce a superimposable diuresis in rats. Naltrexone and nor-BNI, both are effective in antagonizing the effect. CCB does not produce any stereotyped behavior or ataxia in the behavioral assay in doses up to 40 mg/kg s.c., These findings suggest that CCB might be a useful tool to investigate the physiological role of κ opioid receptors.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>7564893</pmid><doi>10.1016/0024-3205(95)02120-8</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0024-3205 |
| ispartof | Life sciences (1973), 1995, Vol.57 (16), p.1487-1495 |
| issn | 0024-3205 1879-0631 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77517639 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer Analgesics - pharmacology Animals Benzomorphans - pharmacology Binding, Competitive CCB Male Mice Morphine - pharmacology Naltrexone - pharmacology Pyrrolidines - pharmacology Rats Rats, Sprague-Dawley Receptors, Opioid, delta - drug effects Receptors, Opioid, kappa - agonists Receptors, Opioid, kappa - drug effects specific κ opioid agonist δ binding κ binding μ binding σ 1 binding |
| title | CCB, a novel specific κ opioid agonist, which discriminates between opioid and σ 1 recognition sites |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T02%3A56%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CCB,%20a%20novel%20specific%20%CE%BA%20opioid%20agonist,%20which%20discriminates%20between%20opioid%20and%20%CF%83%201%20recognition%20sites&rft.jtitle=Life%20sciences%20(1973)&rft.au=Ronsisvalle,%20G.&rft.date=1995&rft.volume=57&rft.issue=16&rft.spage=1487&rft.epage=1495&rft.pages=1487-1495&rft.issn=0024-3205&rft.eissn=1879-0631&rft_id=info:doi/10.1016/0024-3205(95)02120-8&rft_dat=%3Cproquest_pubme%3E77517639%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77517639&rft_id=info:pmid/7564893&rft_els_id=0024320595021208&rfr_iscdi=true |